Experience of isavuconazole use for the treatment of mucormycosis: a clinical case and analysis of registry data

Abstract

Isavuconazole is a new generation triazol that has been using for the treatment of mucormycosis in the Russian Federation since 2021. A clinical case and results of a prospective multicenter study of the clinical features and results of mucormycosis treatment in patients receiving isavuconazole are presented. The study included 22 adult patients with mucormycosis, the median age of patients was 62 years (18 – 91), men – 64%. Тhe main underlying diseases were COVID-19 (77%), diabetes mellitus (45%), and hematological diseases (18%). The main locations of mucormycosis were paranasal sinuses (82%) and associated osteomyelitis (63%), orbit (50%), central nervous system (36%), lungs (18%), skin and soft tissues (18%), and kidneys (5%). Isavuconazole was used in all patients, as a monotherapy – in 45% of patients. To make a diagnosis of mucormycosis, the EORTC/MSG ERC criteria for the diagnosis of mycoses, 2020 were used. Survival of patients receiving isavuconazole was 95% (all-cause mortality).